Gut Robert 4
4 · uniQure N.V. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
uniQure (QURE) Director Robert Gut Exercises Options and Sells Shares
What Happened
- Robert Gut, a director of uniQure N.V. (QURE), exercised stock options to acquire 2,645 shares (exercise price $16.04; total cost $42,426) and then sold shares in the open market.
- Open-market sales on June 10–11, 2026 totaled 10,278 shares for combined gross proceeds of approximately $270,486 (sales at roughly $26.01–$27.25 per share).
- The filing also reports grants/awards totaling 21,530 shares (7,550 and 13,980 units) as awards/derivative acquisitions (restricted share units / awards subject to vesting).
Key Details
- Dates: primary transactions occurred June 10, 2026 (exercise, sales, grants) and June 11, 2026 (additional sale); report filed June 12, 2026 (timely).
- Sales detail (cash proceeds):
- 2,645 shares sold @ $26.07 = $68,955
- 3,127 shares sold @ $26.03 = $81,396
- 1,780 shares sold @ $26.05 = $46,369
- 2,726 shares sold @ $27.06 = $73,766
(weighted-price ranges reported in the filing for the various blocks: approx. $26.01–$27.25)
- Option exercise: 2,645 shares acquired by exercise at $16.04 per share ($42,426). Some derivative entries in the filing reflect the mechanics of option conversion/exercise.
- Awards: 7,550 restricted share units (RSUs) and 13,980 units shown as grants/derivative acquisitions; RSUs vesting terms cited in the filing (vesting schedules apply).
- Automatic withholding sale: one sale block was reported as an automatic sale on vesting to cover withholding taxes (not a discretionary trade).
- Plan / compliance: transactions were effected under a Rule 10b5-1 sales plan adopted July 8, 2025.
- Shares owned after the transactions: not specified in the excerpt provided (aggregate holdings not included here).
Context
- This was primarily a sale of shares and represents routine monetization activity rather than a clear directional signal about company prospects. The sequence — exercise of options followed by sales the same day — is consistent with a cashless exercise/monetization.
- The presence of a 10b5-1 plan and an automatic tax-withholding sale are common mechanisms for insiders to sell shares while avoiding timing concerns; they do not necessarily indicate a change in the insider’s view of the company.
Insider Transaction Report
Form 4
uniQure N.V.QURE
Gut Robert
Director
Transactions
- Exercise/Conversion
Ordinary Shares
[F1]2026-06-10$16.04/sh+2,645$42,426→ 34,987 total - Sale
Ordinary Shares
[F1][F2]2026-06-10$26.07/sh−2,645$68,955→ 32,342 total - Sale
Ordinary Shares
[F1][F3]2026-06-10$26.03/sh−3,127$81,396→ 29,215 total - Sale
Ordinary Shares
[F1][F4]2026-06-10$26.05/sh−1,780$46,369→ 27,435 total - Award
Ordinary Shares
[F5]2026-06-10+7,550→ 34,985 total - Sale
Ordinary Shares
[F6][F7]2026-06-11$27.06/sh−2,726$73,766→ 32,259 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F8]2026-06-10−2,645→ 0 totalExercise: $16.04Exp: 2032-02-24→ Ordinary Shares (2,645 underlying) - Award
Stock Option (Right to Buy)
[F9]2026-06-10+13,980→ 13,980 totalExercise: $26.82Exp: 2036-06-10→ Ordinary Shares (13,980 underlying)
Footnotes (9)
- [F1]The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.18. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.14 . The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- [F5]Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
- [F6]The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
- [F7]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- [F8]The Stock Option vested in full on February 24, 2023.
- [F9]The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Signature
/s/ Christian Klemt, Attorney-in-Fact|2026-06-12